抗癌新藥貴 窮人買不起Anti-cancer drugs for the poor can not afford to buy expensive

抗癌新藥貴 窮人買不起 【詹建富】台灣藥界和不少醫師常抱怨，核准抗癌新藥在台上市的腳步太慢，歐洲腫瘤醫學會中也有學者發表，其實在歐盟，除了法國、瑞士等國引進抗癌藥物較為迅速外，就連英國採用新的抗腫瘤藥物「有如龜步」。 日前在斯德哥爾摩召開的第卅屆歐洲腫瘤醫學會，除了臨床研究外，瑞典卡洛林斯卡研究院教授尼爾斯懷卿蒐集過去10年、歐洲27個國家引進抗癌藥物的速度，根據國際藥業聯盟 (ＩＭＳ)提出系統性分析，特別是被認為抗癌新寵的標靶藥物，獲得各國政府核准上市的差別性。 尼爾斯指出，在大部分西歐國家中，英國引進抗癌新藥的速度，「似乎是少有意外地慢又慢」，相反的，奧地利、瑞士、法國、西班牙等國准許新藥叩關的腳步，則是非常快。以法國為例，該國癌症病人幾乎有許多種類的新藥可供選擇；而在西班牙，則是引進新藥的「領導者」。至於波蘭、匈牙利等東歐國家，則引進抗癌新藥相對緩慢許多。 尼爾斯舉標靶藥物為例，包括治療大腸直腸癌的癌思停、爾必得思、治療肺癌的得紓緩、治療腎癌和肝癌的蕾莎瓦及治療多發性骨髓瘤的萬科，還有治療乳癌的賀癌平，歐洲各國引進新藥的快慢至少有2至3年的差距。特別是賀癌平已上市超過10年之後，還有某些國家的乳癌病人還無福受惠。 不過，尼爾斯強調，造成歐洲各國引進新藥速度的障礙，可能在於許多抗癌新藥非常昂貴，但他認為，有錢的病人照樣可以跨國就醫，反而對某些經濟弱勢的病人難以及早接受治療，而這種差距恐怕是許多人所不樂見。 2008-09-30 Anti-cancer drugs for the poor can not afford to buy expensive 【Zhan Jian-fu in Taiwan and a number of drugs doctors often complain that anti-cancer drug approved in Taiwan listed on the slow pace of the European Oncology Medical Association also published scholar, in fact, the European Union, in addition to France, Switzerland and other countries to introduce more anti-cancer drug Rapid, even Britain's new anti-tumor drugs "like a turtle step." A few days ago in Stockholm held Disa session of the European Oncology Medical Association, in addition to clinical research, the Karolinska Institute of Sweden, Professor Niels Wai Ching collected over the past 10 years, 27 countries in Europe to introduce the speed of anti-cancer drug, according to the International Pharmaceutical Union (IMS) made a systematic analysis, in particular, is considered the favorite target anti-cancer drug, was approved by the Governments of the difference between the listing. Niels pointed out that in most Western European countries, Britain to introduce anti-cancer drug speed, "seems to be little unexpectedly slow and slow," On the contrary, Austria, Switzerland, France, Spain and other countries to allow call-related drugs in the footsteps of , Is very fast. In France, for example, the number of cancer patients almost types of drugs to choose from; in Spain, is the introduction of new drugs, "the leader." As for Poland, Hungary, and other Eastern European countries, the relatively slow introduction of a number of anti-cancer drugs. Niels cited as an example of drug targets, including the treatment of colorectal cancer think of to stop the cancer, have to think of Seoul, the treatment of lung cancer were relieved, and the treatment of renal cell carcinoma Lei Shawa and treatment of liver cancer multiple myeloma Vanke , And the treatment of breast cancer-ping, the introduction of new drugs in Europe the pace of at least 2-3 years of the gap. He in particular has been cancer-listed more than 10 years later, there are some breast cancer patients also benefit from the free-fu. However, Niels stressed that the introduction of new drugs in Europe caused by the speed of the obstacles is that many anti-cancer drugs may be very expensive, but he believes that money can still cross the patient for medical treatment, but the economy vulnerable to some patients as early as possible is difficult to accept Treatment, and this gap is probably not many people would like to see. 2008-09-30 View more information, see the World Journal reported that e-ePaper

瀏覽更多新聞，請看世界日報電子報 ePaper。